Compare PMEC & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMEC | COCP |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 21.6M |
| IPO Year | 2021 | 2011 |
| Metric | PMEC | COCP |
|---|---|---|
| Price | $0.63 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 84.1K | 50.9K |
| Earning Date | 07-24-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.76 |
| 52 Week High | $2.44 | $2.03 |
| Indicator | PMEC | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 52.68 |
| Support Level | $0.51 | $0.98 |
| Resistance Level | $0.80 | $1.22 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 68.75 | 26.53 |
Primech Holdings Ltd is a cleaning business. The Company operates in two segments: commercial cleaning services and robotics. The Company is an established technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The Company generates revenue from services, which include services for general cleaning and maintenance of public and private facilities; cleaning of kitchen facilities of healthcare facilities, hotels and restaurants; and the supply of ad hoc customer; and cleaning services to offices.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.